Nanomaterials in Glioblastoma Research, Diagnosis and Therapy

Glioblastoma (GBM) is a highly malignant brain tumor with complex genetic alterations. This chapter provides an overview of the molecular genetics of GBM, including the genetic alterations that contribute to its pathogenesis, the molecular subtypes of GBM, and potential therapeutic targets for GBM treatment. The genetic alterations in GBM involve multiple signaling pathways, including the receptor tyrosine kinase (RTK) pathway, the p53 pathway, the RB pathway, and the PI3K/AKT/mTOR pathway. GBM is also characterized by molecular subtypes that have distinct genetic alterations and clinical features. Potential therapeutic targets for GBM treatment include RTK inhibitors, PI3K/AKT/mTOR inhibitors, and histone deacetylase inhibitors. However, the development of effective therapies for GBM is challenging due to its genetic heterogeneity and the presence of the blood-brain barrier. Understanding the molecular genetics of GBM is crucial for the development of effective therapies and improving patient outcomes.

Transferable modifications that occur without any mutations in the DNA and can change gene profiling are explained by epigenetics. Epigenetic changes can occur directly on DNA, as well as through histone proteins or non-coding RNAs. Thanks to this, many mechanisms can be reorganized in the organism. As a result of changing the expression levels of genes, the development of many diseases, including cancer, can be promoted. Epigenetic mechanisms such as DNA methylation, Histone Modifications, and non-coding RNA are particularly associated with the formation and development of GBM. It is important to investigate the relevant epigenetic regulation patterns for early diagnosis, treatment, and prevention of poor prognosis of GBM. In this section, the mechanisms of epigenetic modification, which are often observed in GBM, a highly aggressive brain tumor, are introduced. In this way, although the gene base sequence does not change, it is explained how gene profiles change and how they support the development of GBM.

Currently, GBM is treated with chemotherapy, radiotherapy, and surgicalbased approaches. However, these treatments often fail due to the development of resistance mechanisms. The goal of these treatments is to induce DNA damage in tumor cells. If the induced single-strand or double-strand DNA break cannot be repaired, it leads to dangerous lesions and triggers apoptosis in the cell. In contrast, mammals have multiple DNA damage repair mechanisms that utilize different enzymes and pathways. These repair mechanisms are more developed in cancer cells and contribute to their resistance to chemotherapy and radiation therapy. Resistance mechanisms are commonly observed in the treatment of GBM, which is an aggressive type of cancer. This section explains the mechanisms of resistance that develop in response to DNA damage in GBM, their causes, and various strategies for inhibiting resistance.

Glioblastoma is a highly aggressive and difficult-to-treat brain cancer that has a poor prognosis. Immunotherapy has emerged as a promising approach for the treatment of glioblastoma, as it harnesses the power of the immune system to target and kill cancer cells. However, the efficacy of immunotherapy is limited by several factors, including the immunosuppressive microenvironment of the brain and the lack of effective drug delivery systems. Biomaterials have the potential to improve the efficiency of immunotherapy of glioblastoma treatment by enhancing drug delivery, modulating the immune response, and overcoming the immunosuppressive microenvironment of the brain. This chapter summarizes recent advances in biomaterials for the treatment of glioblastoma, with a focus on their potential to improve the efficiency of immunotherapy. The chapter highlights the potential of biomaterials to enhance drug delivery, modulate the immune response, and overcome the immunosuppressive microenvironment of the brain, providing more effective and targeted therapies for patients with glioblastoma. Further research is needed to optimize the design and performance of biomaterial-based immunotherapies and to evaluate their safety and efficacy in humans.

 This book chapter focuses on the development of electrochemical biosensors based on 2-D nanomaterials for the diagnosis of glioblastoma, a highly aggressive and malignant form of brain cancer. 2-D nanomaterials, such as graphene and transition metal dichalcogenides, have unique electronic, optical, and mechanical properties that make them ideal candidates for the development of biosensors. These materials can be functionalized with biological molecules to selectively detect biomarkers associated with glioblastoma. Electrochemical biosensors based on 2-D nanomaterials work by detecting changes in the electrical properties of the material in response to the presence of a target biomarker. This chapter highlights recent advances in the development of 2- D nanomaterial-based electrochemical biosensors for the diagnosis of glioblastoma. These biosensors have the potential to revolutionize the way glioblastoma is diagnosed and treated and to significantly improve patient outcomes. The chapter also discusses the challenges and future directions of this field, including the need for further optimization and validation of these biosensors for clinical use. 

Glioblastoma (GBM) is a highly aggressive and malignant form of brain cancer that is difficult to treat due to the blood-brain barrier (BBB) and drug resistance. Gold nanoparticles (AuNPs) and cold plasma have emerged as promising approaches for GBM therapy due to their unique physical and chemical properties. AuNPs can be engineered to selectively target cancer cells and deliver therapeutic agents, while cold plasma can induce apoptosis and inhibit tumor growth. This book chapter reviews the recent advances in the use of AuNPs and cold plasma for GBM therapy. The chapter discusses the mechanisms of action of AuNPs and cold plasma, as well as the challenges and opportunities for their clinical translation. The chapter also highlights the potential of combining AuNPs and cold plasma for synergistic GBM therapy. Overall, this book chapter provides a comprehensive overview of the current state of the art in the use of AuNPs and cold plasma for GBM therapy. 

Brain cancer is a complex and challenging disease to treat due to its location and the blood-brain barrier (BBB), which makes it difficult for therapeutic agents to reach the tumor site. Resonance imaging and therapy have emerged as promising approaches for the diagnosis and treatment of brain cancer. Resonance imaging techniques, such as magnetic resonance imaging (MRI), can be used to detect brain tumors and monitor their growth. Resonance therapy, such as chemotherapy, radiation therapy, and immunotherapy, can be used to destroy cancer cells. Combinational nanomedicine approaches that combine resonance imaging and therapy can be used to guide the delivery of therapeutic agents to brain tumors. Nanoparticles can be used as contrast agents and drug delivery vehicles, which can be functionalized with targeting moieties to selectively target brain tumor cells. Resonance imaging can then be used to monitor the accumulation and distribution of these nanoparticles in the brain, as well as the response of brain tumors to therapy. Therapeutic agents can also be delivered to brain tumors using resonance therapy. Chemotherapy and radiation therapy can be combined with immunotherapy to enhance the efficacy of treatment. The combination of resonance imaging and therapy as a combinational nanomedicine approach offers several advantages for the diagnosis and treatment of brain cancer. Resonance imaging provides high-resolution images of the brain, allowing for the precise targeting of brain tumors. Resonance therapy offers a non-invasive and targeted approach to the treatment of brain tumors. Combinational nanomedicine approaches can also enhance the efficacy and specificity of therapeutic agents for brain cancer. Overall, the combination of resonance imaging and therapy as a combinational nanomedicine approach offers a promising strategy for the diagnosis and treatment of brain cancer. Further research is needed to optimize and personalize this approach for each patient's tumor, as well as to evaluate its safety and efficacy in clinical trials.

 Brain cancer is a highly aggressive and malignant disease that is difficult to treat due to the blood-brain barrier (BBB), which limits the delivery of therapeutic agents to the tumor site. Oral delivery nanostructures offer a promising approach for the treatment of brain cancer. Nanostructures such as liposomes, solid lipid nanoparticles, polymeric nanoparticles, and dendrimers can be used as drug-delivery vehicles, allowing for the targeted and controlled release of therapeutic agents. However, there are several challenges associated with the oral delivery of nanostructures to the brain, including the BBB. Strategies for overcoming the BBB, such as functionalization with targeting moieties and the use of BBB-disrupting agents, have been developed to improve drug delivery to the brain. There is growing research on the use of oral delivery nanostructures for brain cancer treatment. Liposomes, solid lipid nanoparticles, and polymeric nanoparticles have been investigated for their ability to deliver therapeutic agents to brain tumors. These nanostructures offer advantages such as improved drug stability, prolonged circulation time, and targeted drug delivery to the brain. The development of strategies for overcoming the BBB and the use of targeted drug delivery systems can improve the efficacy and safety of brain cancer treatment.